论文部分内容阅读
180例AMI患者给予尿激酶溶栓治疗。结果有和无DM组的血管再通率分别为56.9和74.6%(P<0.05),出血等不良反应发生率为7.1%和4.4%(P<0.05);死亡率为21.4%和5.97%(P<0.05),溶栓后五周内再发心肌缺血事件的发生率分别为14.2%和2.9%(P<0.05)心脏射血分数EF值分别为52.1±11.1、60.9±10.4(P<0.05)。结论AMI患者合并DM溶栓治疗血管再通率明显低于无DM患者且近期预后亦差。
180 cases of AMI patients given urokinase thrombolysis. Results The rate of recanalization was 56.9% and 74.6% respectively in the DM group and non-DM group (P <0.05). The incidence of adverse reactions such as hemorrhage was 7.1% and 4.4% (P <0.05), and the mortality rates were 21.4% and 5.97% P <0.05). The incidences of recurrent myocardial ischemia within five weeks after thrombolysis were 14.2% and 2.9%, respectively (P <0.05). The EF values of cardiac ejection fraction were 52.1 ± 11.1 and 60.9 ± 10.4, respectively (P < 0.05). Conclusion AMI patients with DM thrombolytic therapy of vascular recanalization rate was significantly lower than those without DM and the recent prognosis is poor.